IL-7 promotes CXCR3 ligand-dependent T cell antitumor reactivity in lung cancer

Journal of Immunology

Volumn 182, Issue 11, 2009, Pages 6951-6958

  Andersson, Åsa ^a   Yang, Seok Chul ^c   Huang, Min ^a,b,d   Zhu, Li ^a,b,d   Kar, Upendra K ^a   Batra, Raj K ^a,b,d   Elashoff, David ^a   Strieter, Robert M ^e   Dubinett, Steven M ^a,b,d   Sharma, Sherven ^a,b,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Seoul National University Hospital   (South Korea)

^d VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^e UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIM PROTEIN; CD69 ANTIGEN; CHEMOKINE RECEPTOR CXCR3; CXCL9 CHEMOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 12; INTERLEUKIN 7 RECEPTOR; RECOMBINANT INTERLEUKIN 7; SMAD7 PROTEIN; TRANSCRIPTION FACTOR FOXP3; CXCL10 PROTEIN, HUMAN; CXCL9 PROTEIN, HUMAN; CXCR3 PROTEIN, HUMAN; INTERLEUKIN 7;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOLYSIS; IMMUNE RESPONSE; IMMUNOREACTIVITY; LEWIS CARCINOMA; LYMPHOCYTE SUBPOPULATION; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR VOLUME; ANIMAL; CYTOTOXICITY; DRUG EFFECT; IMMUNOLOGY; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; CARCINOMA, LEWIS LUNG; CHEMOKINE CXCL10; CHEMOKINE CXCL9; CYTOTOXICITY, IMMUNOLOGIC; IMMUNITY, CELLULAR; INTERLEUKIN-7; MICE; RECEPTORS, CXCR3; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY; TUMOR BURDEN;

EID: 67449119127     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0803340     Document Type: Article

References (47)

1. Zou, W. 2005. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 5: 263-274.
2. Johnson, S. K., K. M. Kerr, A. D. Chapman, M. M. Kennedy, G. King, J. S. Cockburn, and R. R. Jeffrey. 2000. Immune cell infiltrates and prognosis in primary carcinoma of the lung. Lung Cancer 27: 27-35.
3. + T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br. J. Cancer 94: 275-280.
4. Dieu-Nosjean, M. C., M. Antoine, C. Danel, D. Heudes, M. Wislez, V. Poulot, N. Rabbe, L. Laurans, E. Tartour, L. de Chaisemartin, et al. 2008. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J. Clin. Oncol. 26: 4410-4417.
5. Fry, T. J., and C. L. Mackall. 2005. The many faces of IL-7: from lymphopoiesis to peripheral T cell maintenance. J. Immunol. 174: 6571-6576.
6. Fry, T. J., E. Connick, J. Falloon, M. M. Lederman, D. J. Liewehr, J. Spritzler, S. M. Steinberg, L. V. Wood, R. Yarchoan, J. Zuckerman, et al. 2001. A potential role for interleukin-7 in T-cell homeostasis. Blood 97: 2983-2990.
7. Managlia, E. Z., A. Landay, and L. Al-Harthi. 2005. Interleukin-7 signalling is sufficient to phenotypically and functionally prime human CD4 naive T cells. Immunology 114: 322-335.
8. Aspinall, R., S. Henson, J. Pido-Lopez, and P. T. Ngom. 2004. Interleukin-7: an interleukin for rejuvenating the immune system. Ann. NY Acad. Sci. 1019: 116-122.
9. Freitas, A. A., and B. B. Rocha. 1993. Lymphocyte lifespans: homeostasis, selection and competition. Immunol. Today 14: 25-29.
10. Fry, T. J., and C. L. Mackall. 2002. Interleukin-7: from bench to clinic. Blood 99: 3892-3904.
11. Jicha, D. L., J. J. Mule, and S. A. Rosenberg. 1991. Interleukin 7 generates antitumor cytotoxic T lymphocytes against murine sarcomas with efficacy in cellular adoptive immunotherapy. J. Exp. Med. 174: 1511-1515.
12. + natural killer cells. J. Immunol. 147: 2208-2214.
13. Mazzucchelli, R., and S. K. Durum. 2007. Interleukin-7 receptor expression: intelligent design. Nat. Rev. Immunol. 7: 144-154.
14. Bradley, L. M., L. Haynes, and S. L. Swain. 2005. IL-7: maintaining T-cell memory and achieving homeostasis. Trends Immunol. 26: 172-176.
15. Sharma, S., R. K. Batra, S. C. Yang, S. Hillinger, L. Zhu, K. Atianzar, R. M. Strieter, K. Riedl, M. Huang, and S. M. Dubinett. 2003. Interleukin-7 gene-modified dendritic cells reduce pulmonary tumor burden in spontaneous murine bronchoalveolar cell carcinoma. Hum. Gene Ther. 14.
16. Sogn, J. A. 1998. Tumor immunology: the glass is half full. Immunity 9: 757-763.
17. Batra, R. K., Y. Lin, S. Sharma, M. Dohadwala, J. Luo, M. Pold, and S. M. Dubinett. 2003. Non-small cell lung cancer-derived soluble mediators enhance apoptosis in activated T lymphocytes through an IκB kinase-dependent mechanism. Cancer Res. 63: 642-646.
18. Yoshino, I., T. Yano, M. Murata, T. Ishida, K. Sugimachi, G. Kimura, and K. Nomoto. 1992. Tumor-reactive T-cells accumulate in lung cancer tissues but fail to respond due to tumor cell-derived factor. Cancer Res. 52: 775-781.
19. + T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 61: 4766-4772.
20. Woo, E. Y., H. Yeh, C. S. Chu, K. Schlienger, R. G. Carroll, J. L. Riley, L. R. Kaiser, and C. H. June. 2002. Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J. Immunol. 168: 4272-4276.
21. Sakaguchi, S. 2000. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 101: 455-458.
22. + T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 163: 5211-5218.
23. Onizuka, S., I. Tawara, J. Shimizu, S. Sakaguchi, T. Fujita, and E. Nakayama. 1999. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor α) monoclonal antibody. Cancer Res. 59: 3128-3133. (Pubitemid 29316012)
24. + regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J. Exp. Med. 194: 823-832.
25. +/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl. Acad. Sci. USA 102: 18538-18543.
26. Alvaro, T., M. Lejeune, M. T. Salvado, C. Lopez, J. Jaen, R. Bosch, and L. E. Pons. 2006. Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. J. Clin. Oncol. 24: 5350-5357.
27. Galon, J., A. Costes, F. Sanchez-Cabo, A. Kirilovsky, B. Mlecnik, C. Lagorce-Pages, M. Tosolini, M. Camus, A. Berger, P. Wind, et al. 2006. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313: 1960-1964.
28. Gao, Q., S. J. Qiu, J. Fan, J. Zhou, X. Y. Wang, Y. S. Xiao, Y. Xu, Y. W. Li, and Z. Y. Tang. 2007. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J. Clin. Oncol. 25: 2586-2593.
29. Belperio, J. A., M. P. Keane, M. D. Burdick, J. P. Lynch, 3rd, Y. Y. Xue, K. Li, D. J. Ross, and R. M. Strieter. 2002. Critical role for CXCR3 chemokine biology in the pathogenesis of bronchiolitis obliterans syndrome. J. Immunol. 169: 1037-1049.
30. Kiertscher, S. M., J. Luo, S. M. Dubinett, and M. D. Roth. 2000. Tumors promote altered maturation and early apoptosis of monocyte-derived dendritic cells. J. Immunol. 164: 1269-1276.
31. + T cells enables preservation of a naive repertoire. J. Immunol. 161: 5909-5917.
32. Komschlies, K. L., T. A. Gregorio, M. E. Gruys, T. C. Back, C. R. Faltynek, and R. H. Wiltrout. 1994. Administration of recombinant human IL-7 to mice alters the composition of B-lineage cells and T cell subsets, enhances T cell function and induces regression of established metastases. J. Immunol. 152: 5776-5784.
33. Bonecchi, R., G. Bianchi, P. P. Bordignon, D. D'Ambrosio, R. Lang, A. Borsatti, S. Sozzani, P. Allavena, P. A. Gray, A. Mantovani, and F. Sinigaglia. 1998. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J. Exp. Med. 187: 129-134.
34. Yang, L., and D. P. Carbone. 2004. Tumor-host immune interactions and dendritic cell dysfunction. Adv. Cancer Res. 92: 13-27.
35. Dubinett, S., S. Sharma, M. Huang, J. Mao, and R. Batra. 2004. Lung cancer and immune dysfunction. In Current Clinical Oncology: Cancer Immunotherapy at the Crossroads: How Tumors Evade Immunity and What Can be Done, Vol. 18. James H. Finke and Ronald M. Bukowski, eds. Humana, Totowa, NJ, pp. 335-349.
36. Ng, C. S., A. C. Novick, C. S. Tannenbaum, R. M. Bukowski, and J. H. Finke. 2002. Mechanisms of immune evasion by renal cell carcinoma: tumor-induced T-lymphocyte apoptosis and NFκB suppression. Urology 59: 9-14.
37. + T cells. J. Immunol. 175: 1483-1490.
38. Yamaguchi, T., and S. Sakaguchi. 2006. Regulatory T cells in immune surveillance and treatment of cancer. Semin. Cancer Biol. 16: 115-123.
39. + T regulatory cells. Nat. Immunol. 4: 337-342.
40. Hori, S., T. Nomura, and S. Sakaguchi. 2003. Control of regulatory T cell development by the transcription factor Foxp3. Science 299: 1057-1061.
41. + regulatory T cells. Nat. Immunol. 4: 330-336.
42. Huang, M., S. Sharma, L. X. Zhu, M. P. Keane, J. Luo, L. Zhang, M. D. Burdick, Y. Q. Lin, M. Dohadwala, B. Gardner, et al. 2002. IL-7 inhibits fibroblast TGF-β production and signaling in pulmonary fibrosis. J. Clin. Invest. 109: 931-937.
43. Ebisawa, T., M. Fukuchi, G. Murakami, T. Chiba, K. Tanaka, T. Imamura, and K. Miyazono. 2001. Smurf1 interacts with transforming growth factor-β type I receptor through Smad7 and induces receptor degradation. J. Biol. Chem. 276: 12477-12480.
44. - T cells through Foxp3 induction and down-regulation of Smad7. J. Immunol. 172: 5149-5153.
45. + T-regulatory cells. J. Immunother. 29: 313-319.
46. + regulatory T cell activity in both humans and mice. J. Immunol. 172: 834-842.
47. + T regulatory cell activities in lung cancer. Cancer Res. 65: 5211-5220.